Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Vorinostat × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 32 Other hematologic neoplasm 22 Thoracic 15 CNS 15 Breast 12 Sarcoma 8 Dermatologic 8 Plasma cell 6 Myeloid 6 Genitourinary 6 Head & Neck 5 Gastrointestinal 5 Classical hematology 3 Gynecologic 2 Tumor-Agnostic 1 Other solid neoplasm 1 Endocrine 1

Conditions

Interventions

Paclitaxel 25 Carboplatin 25 pembrolizumab 20 Gemcitabine 20 Nivolumab 17 Cisplatin 15 Bevacizumab 13 Erlotinib Hydrochloride 12 Pemetrexed 11 Fluorouracil 11 Capecitabine 11 Irinotecan 10 Ipilimumab 10 Docetaxel 10 130-nm albumin-bound paclitaxel 9 eribulin 8 Leucovorin 8 Everolimus 8 BI 6727 8 Albumin-Bound Paclitaxel 8 olaparib 7 Oxaliplatin 7 Cyclophosphamide 7 Afatinib 7 lenvatinib 6 avelumab 6 Trastuzumab 6 Radiotherapy 6 Magnetic Resonance Spectroscopy 6 abemaciclib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00127127 2022-09-13

MK-0683-029

Merck Sharp & Dohme LLC

Phase 1 Completed

18 enrolled 24 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡